Sage Therapeutics has patented a crystalline steroid compound for treating CNS-related disorders like mood disorders, psychotic disorders, anxiety disorders, tremor, and tinnitus. The patent covers methods of making and using the compound. GlobalData’s report on Sage Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Sage Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sage Therapeutics, Anti-inflammatory anesthetics was a key innovation area identified from patents. Sage Therapeutics's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of cns-related disorders with crystalline form c of compound 1

Source: United States Patent and Trademark Office (USPTO). Credit: Sage Therapeutics Inc

A recently granted patent (Publication Number: US11884696B2) discloses a method for treating Central Nervous System (CNS)-related disorders such as mood disorders, psychotic disorders, anxiety disorders, tremor, and tinnitus. The method involves administering a crystalline solid Form C of Compound 1 to subjects in need of treatment. The patent specifies various peaks in the X-ray diffraction pattern of the compound, indicating its unique crystalline structure.

Specifically, the method targets mood disorders like treatment-resistant depression, major depressive disorder (MDD), postpartum depression (PPD), and perinatal depression, along with psychotic disorders such as bipolar disorder. Additionally, the method extends to treating anxiety disorders like generalized anxiety disorder, tremors like essential tremor, and conditions like tinnitus. The administration of the crystalline solid Form C of Compound 1 can be done through various routes including oral, parenteral, intradermal, intrathecal, intramuscular, subcutaneous, vaginal, buccal, sublingual, rectal, topical, inhalation, intranasal, or transdermal, providing flexibility in treatment options for patients.

To know more about GlobalData’s detailed insights on Sage Therapeutics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies